Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 12/2006

01-12-2006

Hyperbaric Oxygen Therapy for Malignancy: A Review

Authors: Jurstine Daruwalla, B.Sc, Chris Christophi, MD

Published in: World Journal of Surgery | Issue 12/2006

Login to get access

Abstract

One unique feature of tumors is the presence of hypoxic regions, which occur predominantly at the tumor center. Hypoxia has a major impact on various aspects of tumor cell function and proliferation. Hypoxic tumor cells are relatively insensitive to conventional therapy owing to cellular adaptations effected by the hypoxic microenvironment. Recent efforts have aimed to alter the hypoxic state and to reverse these adaptations to improve treatment outcome. One way to increase tumor oxygen tensions is by hyperbaric oxygen (HBO) therapy. HBO therapy can influence the tumor microenvironment at several levels. It can alter tumor hypoxia, a potent stimulus that drives angiogenesis. Hyperoxia as a result of HBO also produces reactive oxygen species, which can damage tumors by inducing excessive oxidative stress. This review outlines the importance of oxygen to tumors and the mechanisms by which tumors survive under hypoxic conditions. It also presents data from both experimental and clinical studies for the effect of HBO on malignancy.
Literature
1.
Vaupel P, et al. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 1990;277:895–905PubMed
2.
Tandara AA, et al. Oxygen in wound healing—more than a nutrient. World J Surg 2004;28:294–300PubMed
3.
Grolman RE, et al. Transcutaneous oxygen measurements predict a beneficial response to hyperbaric oxygen therapy in patients with nonhealing wounds and critical limb ischemia. Am Surg 2001;67:1072–1080PubMed
4.
Hammarlund C, et al. Hyperbaric oxygen treatment of healthy volunteers with U.V.-irradiated blister wounds. Burns 1991;17:296–301PubMed
5.
Thom SR, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474–480PubMed
6.
Weaver LK, et al. Hyperbaric oxygen for acute carbon monoxide poisoning.N Engl J Med 2002;347:1057–1067PubMed
7.
Dean BS, et al. Coma reversal with cerebral dysfunction recovery after repetitive hyperbaric oxygen therapy for severe carbon monoxide poisoning. Am J Emerg Med 1993;11:616–618PubMed
8.
Hawkins M, et al. Severe carbon monoxide poisoning: outcome after hyperbaric oxygen therapy. Br J Anaesth 2000;84:584–586PubMed
9.
Durmaz E, et al. Carbon monoxide poisoning and hyperbaric oxygen therapy. Br J Nurs 1999;8:1067–1072PubMed
10.
Wilkinson D, et al. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004;139:1339–1345PubMed
11.
Henk JM, et al. Radiotherapy and hyperbaric oxygen in head and neck cancer: final report of first controlled clinical trial. Lancet 1977;2:101–103PubMed
12.
Petre PM, et al. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg 2003;125:85–95PubMed
13.
Mayer R, et al. Hyperbaric oxygen and radiotherapy. Strahlenther Onkol. 2005;181:113–123PubMed
14.
DeCosse JJ, et al. Influence of high-pressure oxygen and chemotherapy on the AMel 4 hamster melanoma. Cancer Res 1966;26:287–292PubMed
15.
Takiguchi N, et al. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. Cancer Chemother Pharmacol 2001;47:11–14PubMed
16.
Huang Z, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol 2003;78:496-502PubMed
17.
Moulder JE, et al. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313–341PubMed
18.
Knisely JP, et al. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 2002;12:525–536PubMed
19.
Puffer HW, et al. Preliminary observations of oxygen levels in microcirculation of tumors in C3H mice. Adv Exp Med Biol 1976;75:605–610PubMed
20.
Kizaka-Kondoh S, et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021–1028PubMed
21.
Brizel DM, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Physics 1997;38:285–289
22.
Dunst J, et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2001;177:469–473PubMed
23.
Hockel M, et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525–4528PubMed
24.
Cvetkovic D, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001;57:821–825PubMed
25.
Shi Q, et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;3711–3721
26.
Cuisnier O, et al. Chronic hypoxia protects against gamma-irradiation-induced apoptosis by inducing bcl-2 up-regulation and inhibiting mitochondrial translocation and conformational change of bax protein. Int J Oncol 2003;23:1033–1041PubMed
27.
Vaupel P, et al. Tumor oxygenation and its relevance to tumor physiology and treatment. Adv Exp Med Biol 2003;510:45–49PubMed
28.
Vaupel P, et al. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335–354PubMed
29.
Hockel M, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–4515PubMed
30.
Bachtiary B, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234–2240PubMed
31.
Hashizume H, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363–1380PubMed
32.
Galmarini CM, et al. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Invest Drugs 2003;4:1416–1421
33.
Chaplin DJ, et al. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987;47:597–601PubMed
34.
Sakamoto M, et al. Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn J Clin Oncol 1993;23:98–104PubMed
35.
Toi M, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045–1049PubMed
36.
Duque JL, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–527PubMed
37.
Karayiannakis AJ, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003;194:119–124PubMed
38.
Jacobsen J, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343–347PubMed
39.
Akbulut H, et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002;20:184–190PubMed
40.
Ikeda E, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761–19766PubMed
41.
Ferrara N, et al. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25PubMed
42.
Leung DW, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309PubMed
43.
Horiuchi A, et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res 2002;22:2697–2702PubMed
44.
Rofstad EK, et al. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 1998;77:897–902PubMed
45.
Ziemer LS, et al. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 2001;3:500–508PubMed
46.
Shweiki D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845PubMed
47.
Plate KH, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–848PubMed
48.
White FC, et al. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 1995;12:289–301PubMed
49.
Levy AP, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333–13340PubMed
50.
Stein I, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998;18:3112–3119PubMed
51.
Schoch HJ, et al. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002;125:2549–2557PubMed
52.
Iyer NV, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149–162PubMed
53.
Wang GL, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510–5514PubMed
54.
Tang N, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485–495PubMed
55.
Forsythe JA, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–4613PubMed
56.
Semenza GL, et al. ‘The metabolism of tumours’: 70 years later. Novartis Found Symp 2001;240:251–264PubMedCrossRef
57.
Kuwabara K, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995;92:4606–4610PubMed
58.
Hartmann A, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578–1583PubMed
59.
Chavey C, et al. IL-8 is a novel marker for breast cancer. Third Int Symp Mol Biol Breast Cancer 2005;7(Suppl 2)
60.
Benoy IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157–7162PubMed
61.
Brown NS, et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;60:6298–6302PubMed
62.
Kunz M, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma: a potential mechanism for high tumor aggressiveness. Am J Pathol 1999;155:753–763PubMed
63.
Giri D, et al. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139–147PubMed
64.
D’Agnano I, et al. DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. Lab Invest 1995;72:432–438PubMed
65.
Van Schaeybroeck S, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11:7480–7489PubMed
66.
Oh MJ, et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 2000;6:4760–4763PubMed
67.
Gazzaniga P, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. clin Cancer Res 2001;7:577–583PubMed
68.
Graeber TG, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91PubMed
69.
Shaw P, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89:4495–4499PubMed
70.
Brown NS, et al. Hypoxia and oxidative stress in breast cancer; oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001;3:323–327PubMed
71.
Bergh J, et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029–1034PubMed
72.
Havrilesky L, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3814–3825PubMed
73.
Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217–221PubMed
74.
Chadeneau C, et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Camcer Res 1995;55:2533–2536
75.
Oishi T, et al. Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer. Obstet Gynecol 1998;91:568–571PubMed
76.
Kuniyasu H, et al. Expression of human telomerase RNA is an early event of stomach carcinogenesis. Jpn J Cancer Res 1997;88:103–107PubMed
77.
Kumaki F, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001;188–195
78.
Hiyama K, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;895–902
79.
Minamino T, et al. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol 2001;3336–3342
80.
Ravi R, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34–44PubMed
81.
Koukourakis MI, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830–1832PubMed
82.
Hockenbery D, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336PubMed
83.
Lowe SW, et al. Apoptosis in cancer. Carcinogenesis 2000;21:485–495PubMed
84.
Warburg O, et al. On growth of cancer cells in media in which glucose is replaced by galactose. Hoppe Seylers Z Physiol Chem 1967;348:1686–1687PubMed
85.
Kondo Y, et al. Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. J Urol 2005;173:1762–1766PubMed
86.
Semenza GL, et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757–23763PubMed
87.
Webster KA, et al. Coordinate reciprocal trends in glycolytic and mitochondrial transcript accumulations during the in vitro differentiation of human myoblasts. J Cell Physiol 1990;142:566–573PubMed
88.
Maxwell PH, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104–8109PubMed
89.
Bustamante E, et al. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 1977;74:3735–3739PubMed
90.
Mathupala SP, et al. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995;270:16918–16925PubMed
91.
Lu H, et al. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis: oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Biol Chem 2002;277:23111–23115PubMed
92.
Dang CV, et al. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 1997;29:345–354PubMed
93.
Elstrom RL, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892–3899PubMed
94.
Cohen G, et al. Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes. Biochemistry 1963;2:1420–1428PubMed
95.
Talior I, et al. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 2003;285:E295–E302PubMed
96.
97.
Aw TY. Cellular redox: a modulator of intestinal epithelial cell proliferation. News Physiol Sci 2003;18:201–204PubMed
98.
Kamata H, et al. Redox regulation of cellular signalling. Cell Signal 1999;11:1–14PubMed
99.
Benhar M, et al. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002;3:420–425PubMed
100.
Blokhina O, et al. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann bot 2003; 91(Spec No):179–194PubMed
101.
Sharkey S. Current indications for hyperbaric oxygen therapy. Austr Defence Force Health 2000;1:64–72
102.
Jackson AL, et al. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477:7–21PubMed
103.
Szatrowski TP, et al. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–798PubMed
104.
Wiseman H, et al. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313( Pt 1):17–29PubMed
105.
Kuhn MA. Oxygen free radicals and antioxidants. AJN Am J Nurs 2003;103:58–62
106.
Laurent A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005;65:948–956PubMed
107.
Behrend L, et al. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441–1444PubMed
108.
Arnold RS, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A 2001;98:5550–5555PubMed
109.
Suh YA, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401:79–82PubMed
110.
Shen H, et al. Importance of glutathione and associated enzymes in drug response. Oncol Res 1997;9:295–302PubMed
111.
Harrison LB, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492–508PubMed
112.
Kaelin CM, et al. The effects of hyperbaric oxygen on free flaps in rats. Arch Surg 1990;125:607–609PubMed
113.
Kong Q, et al. A threshold concept for cancer therapy. Med Hypotheses 2000;55:29–35PubMed
114.
Hileman EO, et al. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209–219PubMed
115.
Portakal O, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279–284PubMed
116.
Choi AM, et al. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996;15:9–19PubMed
117.
Toyokuni S, et al. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1–3PubMed
118.
Zhou S, et al. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151–157PubMed
119.
Gackowski D, et al. Persistent oxidative stress in colorectal carcinoma patients. Int J Cancer 2002;101:395–397PubMed
120.
Goda N, et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359–369PubMed
121.
Baish JW, et al. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 1996;51:327–346PubMed
122.
Alagoz T, et al. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer 1995;75:2313–2322PubMed
123.
Thom SR. Hyperbaric Oxygen Therapy: A Committee Report. Bethesda, Undersea and Hyperbaric Medical Society, 1992;20814
124.
Zamboni WA, et al. The effect of acute hyperbaric oxygen therapy on axial pattern skin flap survival when administered during and after total ischemia. J Reconstr Microsurg 1989;5:343–350PubMed
125.
Erdmann D, et al. Skin allograft rejection and hyperbaric oxygen treatment in immune-histoincompatible mice. Undersea Hyperb Med 1995;22:395–399PubMed
126.
Granowitz EV, et al. Exposure to increased pressure or hyperbaric oxygen suppresses interferon-gamma secretion in whole blood cultures of healthy humans. Undersea Hyperb Med 2002;29:216–225PubMed
127.
Marx RE, et al. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 1990;160:519–524PubMed
128.
Meltzer T, et al. The effect of hyperbaric oxygen on the bursting strength and rate of vascularization of skin wounds in the rat. Am Surg 1986;52:659–662PubMed
129.
Feldmeier J, et al. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med 2003;30:1–18PubMed
130.
Hunt TK. The physiology of wound healing. Ann Emerg Med 1988;17:1265–1273PubMed
131.
Marx RE, et al. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 1987;64:379–390PubMed
132.
Marx RE, Johnson RP. Problem wounds in oral and maxillofacial surgery: the role of hyperbaric oxygen. In: Davis IC, Hunt TK, editors, Problem Wounds: the Role of Oxygen. New York, Elsevier, 1988; 65–123
133.
Phillips SJ. Physiology of wound healing and surgical wound care. ASAIO J 2000;46:S2–S5PubMed
134.
Conconi MT, et al. Effects of hyperbaric oxygen on proliferative and apoptotic activities and reactive oxygen species generation in mouse fibroblast 3T3/J2 cell line. J Invest Med 2003;51:227–232
135.
Lian QL, et al. Effects of hyperbaric oxygen on S-180 sarcoma in mice. Undersea Hyperb Med 1995;22:153–160PubMed
136.
Johnson RJR, Lauchlan SC. Epidermoid carcinoma of the cervix treated by 60Co therapy and hyperbaric oxygen. In: Proceedings of the third International Congress on Hyperbaric Medicine, 1966;648–652
137.
Shewell J, et al. The effect of hyperbaric oxygen treatment on pulmonary metastasis in the C3H mouse. Eur J Cancer (Oxf) 1980;16:253–259
138.
McMillan T, et al. The effect of hyperbaric oxygen on oral mucosal carcinoma. Laryngoscope 1989;99:241–244PubMed
139.
Valaitis J, et al. Effect of hyperbaric oxygen and nitrogen mustard (NSC-762) on Ehrlich ascites tumor. Cancer Chemother Rep 1968;52(Pt 1):405–412PubMed
140.
Cade IS, et al. Megavoltage radiotherapy in hyperbaric oxygen: a controlled trial. Cancer 1967;20:817–821PubMed
141.
Eltorai I, et al. Does hyperbaric oxygenation provoke an occult carcinoma in man? In: Proceedings of the VIII International Conference on Hyperbaric Medicine, North Carolina, 1987;18–27
142.
Bean JW, et al. Reaction of Ehrlich ascites cells in exposure to oxygen at high pressure. Cancer Res 1966;26:2380–2385PubMed
143.
McCredie JA, et al. Effects of hyperbaric oxygen on growth and metastases of the C3HBA tumor in the mouse. Cancer 1966;19:1537–1542PubMed
144.
Suit HD, et al. Effect of daily exposure to high pressure oxygen on tumor growth. Am J Roentgenol Radium Ther Nucl Med 1966;97:1019–1022PubMed
145.
Johnson RE, et al. Hyperbaric oxygen effect on experimental tumor growth. Radiology 1967;88:775–777PubMed
146.
Feder BH, et al. The effect of hyperbaric oxygen on pulmonary metastases in C3H mice. Radiology 1968;90:1181–1184PubMed
147.
Johnson RJR, et al. The effect of hyperbaric oxygen on tumor metastases in mice. Clin Radiol 1971;22:538–540PubMed
148.
Mestrovic J, et al. Suppression of rat tumor colonies in the lung by oxygen at high pressure is a local effect. Clin Exp Metastasis 1990;8:113–119PubMed
149.
Dettmer CM, et al. The effect of increased oxygen tensions upon animal tumor growth. Am J Roentgenolo Radium Ther Nucl Med 1968;102:804–810
150.
Bradfield JJ, et al. Rapid progression of head and neck squamous carcinoma after hyperbaric oxygenation. Otolaryngol Head Neck Surg 1996;114:793–797PubMed
151.
Van den Brenk HA, et al. An analysis of the progression and development of metastases in patients receiving x-radiation in hyperbaric oxygen. Clin Radiol 1967;18:54–61PubMed
152.
Dische S. Hyperbaric oxygen: the Medical Research Council trials and their clinical significance. Br J Radiol 1978;51:888–894PubMed
153.
Perrins DJD, Wiernik G. Controlled trials in carcinoma of the bladder. In: Smith G, editor, Proceedings of the Sixth International Congress on Hyperbaric Medicine. Aberdeen, Scotland, University Press, 1977;253–258
154.
Henk JM. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers? Int J Radiat Oncol Biol Phys 1986;12:1339–1341PubMed
155.
Sealy R, et al. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1986;12:1343–1346PubMed
156.
Granstrom G. Hyperbaric oxygen therapy decreases the rejection rate of osseointegrated implants after radiotherapy. Strahlenther Onkol 1996;172:20–21PubMed
157.
Maier A, et al. Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction. Eur J Cardiothorac Surg 2000;18:649–655PubMed
158.
Gray LH, et al. The concentration of oxygen dissolved in tissue at the time or irradiation as factor in radiotherapy. Br J Radiol 1953;26:638PubMedCrossRef
159.
Chen Q, et al. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 2002;76:197–203PubMed
160.
Teicher BA, et al. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73–81PubMed
161.
Evans JC. Metastasis following radiotherapy in hyperbaric oxygen. Radiology 1969;93:1155–1157PubMed
162.
Martin DF, et al. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987;747–751
163.
Frid IA, et al. Effects of hyperbaric oxygenation on tumor growth. Vopr Onkol 1989;35:970–973PubMed
164.
Granstrom G, Westin T, Lyden E, Bengt C, Magnusson BG, Edstrom S. Hyperbaric oxygenation does not stimulate experimental tumour growth. In: Proceedings from the XVIth EUBS meeting, Amsterdam, 1990;121–129
165.
Headley DB, et al. The effect of hyperbaric oxygen on growth of human squamous cell carcinoma xenografts. Arch Otolaryngol Head Neck Surg 1991;117:1269–1272PubMed
166.
Sklizovic D, et al. Hyperbaric oxygen therapy and squamous cell carcinoma cell line growth. Head Neck 1993;15:236–240PubMed
167.
McDonald KR, et al. Effect of hyperbaric oxygenation on existing oral mucosal carcinoma. Laryngoscope 1996;106:957–959PubMed
168.
Shi Y, et al. Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature. Head Neck 2005;27:362–369PubMed
169.
Johnson RJ, et al. Sequential study on the effect of the addition of hyperbaric oxygen on the 5 year survival rates of carcinoma of the cervix treated with conventional fractional irradiations. Am J Roentgenol Radium Ther Nucl Med 1974;120:111–117PubMed
170.
Bennett MB, Sealy R, Hockly J. The treatment of stage III squamous cell carcinoma of the cervix in air and in hyperbaric oxygen. In: Smith G, editor, Proceedings of the Sixth International Congress on Hyperbaric Oxygen. Aberdeen, Scotland, University press, 1977;247–252
171.
Henk JM, et al. Radiotherapy and hyperbaric oxygen in head and neck cancer: interim report of second clinical trial. Lancet 1977;2:104–105PubMed
172.
Watson ER, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978;51:879–887PubMed
173.
Brady LW, et al. Hyperbaric oxygen therapy for carcinoma of the cervix—stages IIB, IIIA, IIIB and IVA: results of a randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:991–998PubMed
174.
Granstrom G. Tumor recurrence and development of new head and neck cancers after HDO2—treatment a prospective clinical study. In: Proceedings: International Joint Meeting on Hyperbaric and Underwater Medicine, Milan, 1996;47–60
175.
Dische S, et al. Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiother Oncol 1999;53:93–98PubMed
176.
Haffty BG, et al. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial: carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. Cancer J Sci Am 1999;5:341–347PubMed
177.
Haffty BG, et al. Carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. Int J Radiat Oncol Biol Phys 1999;45:13–20PubMed
178.
Kohshi K, et al. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br J Cancer 1999;80:236–241PubMed
179.
Feldmeier JJ, et al. Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Undersea Hyperb Med 1996;23:205–213PubMed
180.
Horsman M, et al. The Oxygen Effect: Basic Clinical Radiobiology, 2nd edition. London, Arnold, 1997
181.
Overgaard J, et al. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10–21PubMed
182.
Lartigau E, at al. Hyperbaric oxygen in the treatment of radio-induced lesions in normal tissues. Presented to the European Society for Therapuetic Radiology and Oncology and European Committee for Hyperbaric Medicine, Lisbon, 2001
183.
Kalns J, et al. The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. Anticancer Res 1998;18:363–367PubMed
184.
Stuhr LE, et al. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 2004;210:35–40PubMed
185.
Narkowicz CK, et al. Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radic Res Commun 1993;19:71–80PubMed
186.
Dennog C, et al. Analysis of oxidative DNA damage and HPRT mutations in humans after hyperbaric oxygen treatment. Mutat Res 1999;431:351–359PubMed
187.
Kalns JE, et al. Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells. In Vitro Cell Dev Biol Anim 1999;35:98–101PubMed
188.
Teas J, et al. Can hyperbaric oxygen therapy reduce breast cancer treatment-related lymphedema? A pilot study. J Womens Health (Larchmt) 2004;13:1008–1018CrossRef
189.
Yarnold J. Phase II randomized study of hyperbaric oxygen therapy versus standard management in women with chronic arm lymphedema after radiotherapy for early breast cancer. Clinical trial in progress, UK, 2004
190.
Maier A, et al. Does hyperbaric oxygen enhance the effect of photodynamic therapy in patients with advanced esophageal carcinoma? A clinical pilot study. Endoscopy 2000;32:42–48PubMed
191.
Tomaselli, et al. Acute effects of combined photodynamic therapy and hyperbaric oxygenation in lung cancer—a clinical pilot study. Lasers Surg Med 2001;28:399–403
Metadata
Title
Hyperbaric Oxygen Therapy for Malignancy: A Review
Authors
Jurstine Daruwalla, B.Sc
Chris Christophi, MD
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 12/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-006-0190-6

Other articles of this Issue 12/2006

World Journal of Surgery 12/2006 Go to the issue

INVITED COMMENTARY

Need for an Individualized and Aggressive Management of Multinodular Goiters of Endemic Zones by Specially Trained Surgeons: Experience in Western Nepal

OriginalPaper

Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study

INVITED COMMENTARY

When Should We be Concerned for Pancreatic Necrosis?

OriginalPaper

Clinical Predictors of Ongoing Infection in Secondary Peritonitis: Systematic Review

OriginalPaper

Evaluation of P-POSSUM and CR-POSSUM Scores in Patients with Colorectal Cancer Undergoing Resection

OriginalPaper

Impact of Etiologic Factors and APACHE II and POSSUM Scores in Management and Clinical Outcome of Acute Intestinal Ischemic Disorders after Surgical Treatment